GlassScriptPhysician profile
Lizandra Anzo
NPI 1376099879
$5,556.23
in general payments reported to CMS, 2019-2025
22 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $256 · 2023: $1,989 · 2024: $1,845 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,268 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,268.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,307.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $716.36 | 2023-2024 | |
| Novo Nordisk INC | $605.15 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $574.24 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $355.03 | 2022-2025 | |
| Pfizer INC. | $293.33 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $256.43 | 2023-2024 | Xarelto |
| Exact Sciences Corporation | $232.48 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $203.74 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $191.75 | 2023-2025 | |
| Glaxosmithkline, LLC. | $160.93 | 2023-2025 | Arexvy, Shingrix |
| Seqirus USA INC | $159.60 | 2024-2025 | Flucelvax, Fluad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.43 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $91.84 | 2023 | |
| Amgen INC. | $87.06 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.84 | 2022-2023 | Steglatro |
| Gilead Sciences, INC. | $47.81 | 2025 | |
| Astellas Pharma US INC | $29.74 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $19.68 | 2023 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $17.87 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.28 | 2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $8.87 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lizandra Anzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.